NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Dyslipidemia Management in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Nonalcoholic fatty liver disease (NAFLD) is the accumulation of hepatic fat in ≥ 5% of hepatocytes in the absence of other etiologies of liver disease….
Lipid Management in Pregnancy and Lactation
Normal pregnancy is characterized by physiologic increases in maternal levels of cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). These lipoproteins are…
Lipid Management in Chronic Kidney Disease
Chronic kidney disease (CKD) ranks among the top five causes of global mortality, affecting approximately 35.5 million people in the United States (US). Despite being…
The Thyroid-Lipid Axis: Implications for Atherosclerosis and Beyond
Dyslipidemia frequently presents in individuals with thyroid dysfunction, attributed to the influence of thyroid hormones on various key metabolic pathways, thereby contributing to an elevated…
Lipid Management in Patients with Chronic Inflammatory Conditions
Immune system activation – i.e., systemic inflammation, plays an essential role in all stages of atherosclerosis, from the development of the fatty streak to acute…
Dyslipidemia and ASCVD in Non-White Ethnic, Racial, and Ancestral Groups
While atherosclerotic cardiovascular disease (ASCVD) and dyslipidemia affect all populations, their impact is far from uniform. Many interwoven factors, including genetics, sociocultural determinants, and environmental…
Case Study: Pharmacotherapy for Dyslipidemia and Metabolic Dysfunction-Associated Steatotic Fatty Liver Disease
Clinical Case The patient is a 67-year-old white gentleman with type 2 diabetes mellitus (T2DM), hypertension (HTN), 20-pack-year smoking history, and dyslipidemia. He presented to…
Novel Advancements in GLP-1 Receptor Agonist Treatment
Introduction Obesity is a complex, chronic medical condition. Although defined by a BMI >30 kg/m2, it is now understood to be much more than a…